{'fraction_non_alphanumeric': 0.03130755064456722, 'fraction_numerical': 0.01289134438305709, 'mean_word_length': 5.325581395348837, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Combination therapy with ZDV and interferon-alpha-2a promotes tumor regression.


 Combined therapy with an intermediate dose of interferon-alpha-2a and ZDV effectively fights tumors in patients with nonvisceral AIDS-related Kaposi's sarcoma. Treatments are generally well tolerated, with the most common adverse effects being neutropenia, anemia, elevated serum transaminase, and weight loss. Patients with CD4+ counts above 100 respond better than those with lower counts, but the protocol should be considered regardless of the CD4+ count.
